Drug Type Monoclonal antibody |
Synonyms SHR 8068, SHR8068 |
Target |
Action inhibitors |
Mechanism CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Hepatocellular Carcinoma | Phase 3 | China | 28 Oct 2024 | |
metastatic non-small cell lung cancer | Phase 3 | China | 01 Mar 2024 | |
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma | Phase 3 | China | 01 Mar 2024 | |
Uterine Cervical Cancer | Phase 2 | China | 01 Mar 2025 | |
HER2 positive Biliary Tract Neoplasms | Phase 2 | China | 26 Feb 2025 | |
Advanced Malignant Solid Neoplasm | Phase 2 | China | 18 Feb 2025 | |
Advanced Urothelial Carcinoma | Phase 2 | China | 04 Nov 2024 | |
Locally Advanced Lung Non-Small Cell Carcinoma | Phase 2 | China | 27 Sep 2024 | |
Advanced biliary tract cancer | Phase 2 | China | 25 Jun 2024 | |
stomach adenocarcinoma | Phase 2 | China | 11 Mar 2024 |
Phase 1/2 | - | dbbsqafbet(pechycudsq) = TRAE led to discontinuation of any study agent in 11.1%, 1.9% and 9.5% of pts for Combo 1, 2, and 3, respectively uckgrgxgnj (fagqivchxv ) View more | Positive | 30 May 2025 |